ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS

扩增的 Gamma/Delta T 细胞的活性

基本信息

  • 批准号:
    6855787
  • 负责人:
  • 金额:
    $ 12.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-06 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Adapted from applicant's abstract) Nowhere are the promises and problems of T cell based therapy, clearer than following bone marrow transplantation (BMT). While on the one hand T cells can induce potentially lethal graft vs. host disease (GVHD), they also are capable of 1) mediating graft vs. tumor (GVT) effects, 2) facilitating hematopoietic stem cell (HSC) engraftment and 3) providing defense against pathogenic organisms commonly encountered in the post-BMT period. Thus, an idealized population of T cells would be one possessing these positive attributes and lacking the negative. vs T cells are a rarely occurring population of T cells whose function is largely unknown. Few studies have evaluated the role of vs T cells in BMT and existing studies present conflicting results. While some have found that vs T cells do not cause GVHD, others implicate vs T in pathogenesis of GHVD. Moreover, studies suggest that vs T cells may mediate GVT, facilitate HSC engraftment and provide defense against a variety of pathogens. Thus, vs T cells potentially are an attractive candidate population for adoptive immunotherapy. Given the paucity of vs T cells in the peripheral blood, immunotheraptic approaches are impractical without methods for the expansion of such a rare population. We recently have discovered that under in vitro activation conditions, the outgrowth of vs T cells is inhibited by alpha/betaTCR+CD8+ T cells. With this information, we have developed methodology for the ex vivo expansion of large numbers of vs T cells. The long-range goal of this project is to determine whether ex vivo expanded T cell populations add benefit to bone marrow transplantation. The objective of this proposal is to evaluate the role of ex vivo expanded vs T cells in animal models of BMT. The central hypothesis to this work is that vs T cells can be ex vivo expanded and that such populations provide important benefits in the post-BMT period. This hypothesis will be tested by pursuing three specific aims: 1) to evaluate the effect of CD8+ T cells on the ex vivo expansion of vs T cells; 2) to determine the in vitro biological characteristics of expanded vs T cells; and 3) to evaluate the in vivo biological activity of expanded vs T cells with respect to GVHD, GVT and facilitation of HSC engraftment. The proposed work is innovative because we will be studying and transferring an otherwise rare population of cells in sensitive animal models of GVHD, GVT and facilitation of engraftment. It is expected that these studies will provide preclinical information regarding the use of expanded vs T cells in the post-BMT setting. This work is significant in that it will examine the interactions between CD8+T cells and vs T cells. Further, we will evaluate how vs T cells function and traffic in the post-BMT setting. The proposed training program is in a dynamic research setting with extensive intellectual and technical support. Thus, the candidate will acquire the skills to secure a faculty position as a pediatric bone marrow transplantation clinical-scientist.
描述

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael R. Verneris其他文献

28: Reduced Risk of Leukemia Relapse after Double UCB Transplantation
  • DOI:
    10.1016/j.bbmt.2007.08.036
  • 发表时间:
    2007-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Michael R. Verneris
  • 通讯作者:
    Michael R. Verneris
Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg)
  • DOI:
    10.1016/j.bbmt.2014.11.054
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Claudio Brunstein;Keli Hippen;Todd E. Defor;David McKenna;Julie Curtsinger;Darin Sumstad;Bruce L. Levine;Carl H. June;Jeffrey S. Miller;Michael R. Verneris;Bruce R. Blazar;John E. Wagner
  • 通讯作者:
    John E. Wagner
Pre-Transplant Serum Biomarkers Predict Early Relapse in Classical Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
  • DOI:
    10.1016/j.bbmt.2014.11.202
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Bryan Trottier;Holly Miller;Qing Cao;Jeffrey S. Miller;Michael R. Verneris;Daniel J. Weisdorf;John Levine;Linda J. Burns
  • 通讯作者:
    Linda J. Burns
Second Allogeneic Hematopoietic Cell Transplantation for Graft Failure: Poorer Outcomes for Neutropenic Graft Failure
  • DOI:
    10.1016/j.bbmt.2014.11.242
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Troy Christopher Lund;Jessica Liegel;Paul Orchard;Qing Cao;Jakub Tolar;Claudio Brunstein;John E. Wagner;Michael R. Verneris;Daniel J. Weisdorf
  • 通讯作者:
    Daniel J. Weisdorf
Preservation of Ovarian Function after Hematopoietic Cell Transplantation (HCT): More Possible Than We Thought?
  • DOI:
    10.1016/j.bbmt.2014.11.264
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rachel Phelan;Elizabeth Mann;Char Napurski;Todd E. Defor;Anna Petryk;Weston P. Miller;John E. Wagner;Michael R. Verneris;Angela R. Smith
  • 通讯作者:
    Angela R. Smith

Michael R. Verneris的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael R. Verneris', 18)}}的其他基金

Biomarkers in pediatric versus adult myelodysplastic syndromes
儿童与成人骨髓增生异常综合征的生物标志物
  • 批准号:
    8892683
  • 财政年份:
    2015
  • 资助金额:
    $ 12.37万
  • 项目类别:
Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune Recovery
淋巴组织诱导剂/NK22 细胞与移植后免疫恢复
  • 批准号:
    8575441
  • 财政年份:
    2013
  • 资助金额:
    $ 12.37万
  • 项目类别:
Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune Recovery
淋巴组织诱导剂/NK22 细胞与移植后免疫恢复
  • 批准号:
    8660608
  • 财政年份:
    2013
  • 资助金额:
    $ 12.37万
  • 项目类别:
Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune Recovery
淋巴组织诱导剂/NK22 细胞与移植后免疫恢复
  • 批准号:
    9392628
  • 财政年份:
    2013
  • 资助金额:
    $ 12.37万
  • 项目类别:
ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS
扩增的 Gamma/Delta T 细胞的活性
  • 批准号:
    6704203
  • 财政年份:
    2001
  • 资助金额:
    $ 12.37万
  • 项目类别:
ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS
扩增的 Gamma/Delta T 细胞的活性
  • 批准号:
    6731099
  • 财政年份:
    2001
  • 资助金额:
    $ 12.37万
  • 项目类别:
ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS
扩增的 Gamma/Delta T 细胞的活性
  • 批准号:
    6703592
  • 财政年份:
    2001
  • 资助金额:
    $ 12.37万
  • 项目类别:
ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS
扩增的 Gamma/Delta T 细胞的活性
  • 批准号:
    6536671
  • 财政年份:
    2001
  • 资助金额:
    $ 12.37万
  • 项目类别:
ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS
扩增的 Gamma/Delta T 细胞的活性
  • 批准号:
    6258622
  • 财政年份:
    2001
  • 资助金额:
    $ 12.37万
  • 项目类别:
Translational Cell Therapy Core
转化细胞治疗核心
  • 批准号:
    8931149
  • 财政年份:
    1997
  • 资助金额:
    $ 12.37万
  • 项目类别:

相似海外基金

The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
  • 批准号:
    DP240102905
  • 财政年份:
    2024
  • 资助金额:
    $ 12.37万
  • 项目类别:
    Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23K28188
  • 财政年份:
    2024
  • 资助金额:
    $ 12.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
  • 批准号:
    2339172
  • 财政年份:
    2024
  • 资助金额:
    $ 12.37万
  • 项目类别:
    Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
  • 批准号:
    10577518
  • 财政年份:
    2023
  • 资助金额:
    $ 12.37万
  • 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23H03498
  • 财政年份:
    2023
  • 资助金额:
    $ 12.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
  • 批准号:
    10676407
  • 财政年份:
    2023
  • 资助金额:
    $ 12.37万
  • 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
  • 批准号:
    22KK0277
  • 财政年份:
    2023
  • 资助金额:
    $ 12.37万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
  • 批准号:
    10599584
  • 财政年份:
    2023
  • 资助金额:
    $ 12.37万
  • 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
  • 批准号:
    10530023
  • 财政年份:
    2022
  • 资助金额:
    $ 12.37万
  • 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
  • 批准号:
    10684172
  • 财政年份:
    2022
  • 资助金额:
    $ 12.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了